Supplementary Material

Figure S1. The definition of tolvaptan dose reduction or discontinuation



Figure S2. Methods of evaluating major adverse effects



Figure S3. Sensitivity analysis: factors associated with tolvaptan dose reduction or discontinuation using eGFR



	Adjusted HRs	95% CI	P-values
Age	1.00	0.99 - 1.01	0.63
Male	0.76	0.44 - 1.32	0.33
eGFR	0.98	0.96 - 0.99	0.002
DM	1.40	0.68 - 2.86	0.36
HT	1.57	0.82 - 2.99	0.17

Abbreviations: eGFR, estimated glomerular filtration rate; DM, Diabetes Mellitus; HT, Hypertension; HRs, Hazard Ratios; CI, Confidence Interval

Figure S4. Secondary outcome: Factors associated with tolvaptan discontinuation



	Adjusted HRs	95% CI	P-values
eGFR <60ml/min/1.73m²	2.15	0.49 - 9.40	0.78
HT	0.78	0.31 - 1.97	0.60

Abbreviations: eGFR, estimated glomerular filtration rate; HT, Hypertension; HRs, Hazard Ratios; CI, Confidence Interval

Table S1. Frequency of major adverse effects

Variables	**Overall**
Overall	n=156
Elevation in aminotransferase, n (%)	6 (3.8)
To > 3×ULN	6 (3.8)
To > 5×ULN	5 (3.2)
To > 10×ULN	4 (2.6)
Missing data	20 (13)
Hypernatremia, n (%)	12 (7.7)
To > 145 mEq/L	12 (7.7)
To > 150 mEq/L	1 (0.64)
To > 160 mEq/L	0 (0)
Missing data	11 (7.1)
Acute kidney injury, n (%)	6 (3.8)
To > 1.5×Baseline serum creatinine	6 (3.8)
To > 2.0×Baseline serum creatinine	5 (3.2)
To > 3.0×Baseline serum creatinine	2 (1.3)
Missing data	20 (13)

Data were presented as unweighted number (percentage) of patients.
Abbreviations: ULN, Upper Limit of the Normal Range